Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Profex Receives $15.5 Million Venture Capital Investment

This article was originally published in PharmAsia News

Executive Summary

Profex, China's first international dermatology firm, received its first round of venture capital worth $15.5 million from Trident Capital and its China partner Mustang Ventures. The new fund will help it penetration into the fast-growing consumables retail market. Profex differs from other domestic pharmaceutical companies in its business model; by acting as a professional drug agency for the world's top pharmaceutical companies, it has exclusive sales rights for China. The firm has established long-term strategic partnerships with Galderma, GlaxoSmithKline, Roche and Bristol-Meyers Squibb, with full responsibility for products' marketing. Industry insiders said that Profex, with over 30 percent of the local dermatology market share and sales exceeding RMB 1 billion, will list in the U.S. when the timing is right. (Click here for more - Chinese Language)

You may also be interested in...

Second Biogen/Eisai Antibody Moves AHEAD, In Asymptomatic Alzheimer’s

More progress for partners’ amyloid-targeting antibody portfolio as they look to demonstrate benefit of early intervention in pre-symptomatic disease in new collaborative Phase III trial.

QUOTED. 14 July 2020. Stephen Furlong.

With the global pandemic leading to a big rise in mental health issues, medtech could have a role to play. The first of a two-part series on mental health focuses on transcranial magnetic stimulation systems. See what Neuronetics’ CEO Stephen Furlong said about it here.

CytoDyn's Leronlimab Suffers Refuse To File Letter; US FDA Concerned About Dosing, Manufacturing

US FDA declines to review the CCR5 antagonist for use in highly treatment-experienced HIV patients. Safety data from an ongoing study should be sufficient to address the agency’s concerns about the higher 700mg dose, CytoDyn management says, but FDA also has questions about the production of the self-injectable syringes.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts